Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Retire These Reactions! | Main | I'll See Your Conflicts, and Raise You? »

October 8, 2009

Hoist, Petard, Etc.

Email This Entry

Posted by Derek

Hmmm. As a colleague just pointed out to me, I've spent some time here defending "me-too" drugs. And just this morning (see the previous post) I take off after what can only be described as "me-too reactions", saying that I don't see the use for so many of them.

Well! The only defense I can offer (until I think of a better one) is that there is no drug category so populated as the aldoxime-to-nitrile conversion is in synthetic chemistry (or acetal formation/deprotection, desilylation, or the other categories I spoke of in that other post). I suppose I might have a tougher time standing up for me-too drugs if there were (say) twenty-nine statins on the market. But still. . ."I'd better put up a post on that", I said. "Better you than someone with a funny pseudonym in your comments section", came the reply.

Comments (7) + TrackBacks (0) | Category: Chemical News | Life in the Drug Labs


COMMENTS

1. John Freskos on October 8, 2009 2:32 PM writes...

I remember ~ 20 years ago when Searle deveolped Daypro as about the 21st NSAID as a 1200 mg horse pill thinking are they crazy. But then it went on and sold ~ 300 to 400 M/year at peak. Guess they had good marketing / sales or something

Permalink to Comment

2. Sili on October 8, 2009 3:10 PM writes...

Awwww.

The situations aren't that parallel. (Of course, I've just heard an egregious ad hominem on Al Gore, so I may be primed for worse cases of implied hypocrisy.)

I think your argument holds water.

Permalink to Comment

3. John Johnson on October 8, 2009 10:07 PM writes...

I think there are about 20 beta blockers on the market, so I think that market has gone through the diminishing marginal returns phase and is well into the why bother phase, but maybe some market analyst has a different opinion.

Permalink to Comment

4. piratechem on October 9, 2009 12:03 AM writes...

Definitely not analogous in terms of multiplicity--way more me-too reactions. However the much larger financial scale of developing a drug vs developing a reaction should get some consideration.

Permalink to Comment

5. RB Woodweird on October 9, 2009 6:39 AM writes...

What do ya mean, funny? Let me understand this cause, I don't know. Maybe it's me, but I'm funny how? I mean, funny like I'm a clown; I amuse you? I make you laugh... I'm here to amuse you? What do you mean funny, funny how? How am I funny?

Anyway, I don't see the parallel at all. So-called me-too drugs have some utility. There are going to be people who tolerate one such drug better than another and people for who one such drug works better than another. Plus, the enormous effort necessary to bring a drug to market means that there are not going to be dozens of very similar drugs.

Reactions, however, have a very different genesis. I'm willing to bet dollars to disposable pipets that each of these little me-too dehydration reactions wasn't dreamed up by someone thinking that the world really really needed another one. They were cooked up by graduate students who just needed a publication or two to get the hell out of graduate school.

Permalink to Comment

6. Analytical Scientist on October 9, 2009 7:33 AM writes...

It's a mater of degree: a couple of me-too's provide depth to the bench, but a new me-too with undistinguished safety/efficacy after the lead is already generic is just excessive. I get annoyed everytime I learn about a new proton pump inhibitor that I was unaware of. To your statin example, new statins are fine...but they better be more potent (and safe!) than Lipitor!

Permalink to Comment

7. JGault on October 10, 2009 7:51 PM writes...

Regulatory authorities have no right to reject safe effective therapies on the basis of non-superiority to existing therapies in a free society. The arguement has been rightfully made many times on this blog that there are always differences which may benifit one patient population over another and equivalent therapies drive down cost as well. The USDA can't keep pork chops off the market because they do not taste as good as a good ribeye, nor can government keep a Ford off the market because it is not as good as a BMW. We have drifted into the sureal when we allow government this level of control. Payers are becoming more agresive in setting the price/benefit bar they will pay for high, and rightfully so, but price/benefit should not be the authority of a free government. We need to be careful in asuming we know who will benefit from certain drugs, and remember that choice is the only true form of wealth. If today's standards were used there would be no Lipitor (It was 4th with no apparent differentiation at the time of approval). The 5th PPI to market still sells >1B/yr, someone is getting some benefit. I just know as a taxpayer I don't want to fund the 200th oxime dehydration, I could care less if it gets published.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
XKCD on Protein Folding
The 2014 Chemistry Nobel: Beating the Diffraction Limit
German Pharma, Or What's Left of It
Sunesis Fails with Vosaroxin
A New Way to Estimate a Compound's Chances?
Meinwald Honored
Molecular Biology Turns Into Chemistry
Speaking at Northeastern